Email updates

Keep up to date with the latest news and content from Infectious Agents and Cancer and BioMed Central.

Open Access Highly Accessed Letter to the Editor

c-Met inhibitors

Anum Mughal1, Hafiz Muhammad Aslam1*, Asfandyar Sheikh12, Agha Muhammad Hammad Khan3 and Shafaq Saleem1

Author Affiliations

1 Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan

2 Pakistan Research Evolution Students’ Society, Karachi, Pakistan

3 Sindh Medical College, Dow University of Health Sciences, Karachi, Pakistan

For all author emails, please log on.

Infectious Agents and Cancer 2013, 8:13  doi:10.1186/1750-9378-8-13

Published: 8 April 2013

Abstract

c-Met is a receptor tyrosine kinase that encodes protein such as hepatocyte growth factor receptor (HGFR). Inappropriate activity of c-Met can cause wide variety of carcinomas. c-Met inhibitor are relatively new class of small molecules that inhibit the enzymatic activity of c-Met tyrosine kinase. Met inhibitors divided into two main classes: class I (SU-11274-like) and class II (AM7-like). The use of c-Met inhibitors with other therapeutic agents could be crucial for overcoming potential resistance as well as for improving overall clinical benefit. Met pathway inhibitors might be used in combination with other treatments, including chemo-, radio- or immunotherapy

Keywords:
c-Met; Tyrosine kinase; Cancer